Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus neoadjuvant chemotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma
ChiCTR2000040034Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Pathological complete response evaluated by a blinded independent review committee and Event-free survival. Started Apr 2021; status: completed.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000040034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040034.